Hyoen Lee, NP
Nurse Practitioner · Timonium, MDNPI 1871859926
Payments from drug & device makers
Across 150 payments — averaging $22.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$359
- Novo Nordisk$302
- Corcept Therapeutics$254
- Amgen$250
- Insulet Corporation$207
- AstraZeneca$186
- plus $2K from 33 others
What the payments were for
- Food & beverage$3,383100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 18 | $359 |
| Novo Nordisk | 15 | $302 |
| Corcept Therapeutics | 7 | $254 |
| Amgen(2 entities) | 10 | $250 |
| Insulet Corporation | 5 | $207 |
| AstraZeneca(2 entities) | 10 | $186 |
| Sanofi-aventis U.S. LLC | 8 | $183 |
| Radius Health, Inc. | 6 | $140 |
| Lilly USA, LLC | 7 | $131 |
| Dexcom, Inc. | 2 | $99 |
| Boehringer Ingelheim | 5 | $87 |
| Xeris Pharmaceuticals, Inc. | 4 | $77 |
| Bayer | 4 | $74 |
| Tandem Diabetes Care, Inc. | 3 | $73 |
| Cequr Corporation | 2 | $67 |
| Novartis | 3 | $66 |
| Embecta Corp. | 2 | $64 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $61 |
| Recordati_rare_diseases_inc. | 3 | $58 |
| Mannkind Corporation | 4 | $57 |
| Medtronic | 3 | $54 |
| Averitas Pharma Inc. | 2 | $50 |
| Almatica Pharma LLC | 2 | $44 |
| Antares Pharma, Inc. | 2 | $39 |
| Abbott | 2 | $39 |
| Kyowa Kirin, Inc. | 2 | $37 |
| Amarin Pharma, Inc. | 2 | $34 |
| BETA Bionics, Inc. | 1 | $34 |
| IBSA Pharma Inc. | 2 | $33 |
| Lifescan, Inc. | 2 | $30 |
| Amneal Pharmaceuticals LLC | 1 | $28 |
| BD | 1 | $28 |
| Neurocrine Biosciences, Inc. | 1 | $27 |
| Ascendis Pharma Endocrinology Inc | 1 | $24 |
| Sequel Med Tech, LLC | 1 | $22 |
| Zealand Pharma US, Inc. | 1 | $21 |
| Regeneron Healthcare Solutions, Inc. | 1 | $17 |
| Azurity Pharmaceuticals, Inc. | 1 | $15 |
| Tolmar, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,383 in reported general payments places this provider in the 90th percentile of 1,562 nurse practitioner providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 124 | $212,167 |
| MounjaroTirzepatide | 108 | $194,403 |
| JardianceEmpagliflozin | 61 | $98,462 |
| Tresiba Flextouch U-200Insulin Degludec | 32 | $82,970 |
| TrulicityDulaglutide | 26 | $54,410 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 28 | $33,192 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 51 | $32,987 |
| JanuviaSitagliptin Phosphate | 28 | $32,102 |
| Tresiba Flextouch U-100Insulin Degludec | 39 | $25,948 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 25 | $25,141 |
| Humalog Kwikpen U-200Insulin Lispro | 12 | $25,013 |
| FarxigaDapagliflozin Propanediol | 22 | $21,080 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 14 | $19,064 |
| Humalog Kwikpen U-100Insulin Lispro | 51 | $17,931 |
| RybelsusSemaglutide | 15 | $17,027 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $131 | $248,814134 claims |
| Novo NordiskOzempic, Rybelsus | $302 | $229,194139 claims |
| Boehringer IngelheimJardiance, Tradjenta | $87 | $115,38384 claims |
| AstraZenecaFarxiga | $186 | $21,08022 claims |
| AbbVieSynthroid | $359 | $6,40676 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $28 | $2,081171 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,562 nurse practitioner providers in Maryland.
Other nurse practitioner in Timonium
- Jennifer MaglianoTimonium$16K
- Morgan GaleRockville$292K
- Sherilyn BrinkleyBaltimore$100K
- Michelle TurnerBaltimore$94K
- Nelli ZafmanLutherville$67K
- Ellen LancasterFallston$52K
- Doris TateEaston$34K
- Zeev NemirovskyBaltimore$19K
- Martha ReilleyAnnapolis$18K
- Stephanie ZwonitzerAnnapolis$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.